Theravance Biopharma, Inc. (TBPH): restructuring charge — Theravance Biopharma Phase 3 CYPRESS study fails; plans 50% workforce cut and strategic review

Theravance Biopharma, Inc.

Phase 3 CYPRESS study of ampreloxetine for nOH in MSA did not meet primary endpoint (OHSA composite); program halted.
Organizational restructuring to reduce cost base ~60% (~$70M) and impact ~50% of workforce; R&D wound down, G&A cut ~50%.
Board's Strategic Review Committee accelerating evaluation of alternatives including a sale of the company.
Preliminary cash $326.5M at Q4 2025; expected ~$400M at Q1 2026 after $25M YUPELRI and $50M TRELEGY milestones received.
YUPELRI FY2025 net sales $266.6M (+12% YoY); company expects ~$60-70M annualized cash flow from restructuring and YUPELRI.

Key facts

Extracted from this filing and checked against the source text.

Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.9

Theravance Biopharma, Inc. announced a restructuring with charges of approximately $5 million to $7 million affecting R&D and G&A functions (approximately 50% of the Company’s overall workforce).

Type: restructuring
Charge: approximately $5 million to $7 million
Affected area: R&D and G&A functions
Headcount: approximately 50% of the Company’s overall workforce

Exact text from the filing

On March 3, 2026, the Company announced an organizational restructuring (the “Restructuring”), which is intended to reduce cost base by approximately 60% (or approximately $70 million) and expected to impact approximately 50% of the Company’s overall workforce. The Restructuring will be implemented over the next two quarters, with the Company expecting to incur approximately $5 million to $7 million in one-time cash severance costs related to the Restructuring.

View on SEC.gov

3 restructurings & charges filed in the last 30 days. Browse all restructurings & charges →

Theravance Biopharma, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-26-022572

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.